Skip to main content
OpenTrials
Completed

NCT Number: NCT01399723

Amoxicillin Versus Benzyl Penicillin for Treatment of Children Hospitalised With Severe Pneumonia

This study seeks to determine whether clinical outcome following initial treatment of severe pneumonia with oral amoxicillin is as effective as the current standard benzyl penicillin. The study will also provide an estimate of the proportion of Kenyan children with severe pneumonia who fail treatment with a single antibiotic.

Completed

Looking for future studies?

Notify Me

Key information

Age range

2 month–59 month

Sex eligibility

All sexes

Study type

Interventional

Phase

Phase 3

Primary location

Kerugoya District Hospital, Kerugoya, Central, Kenya

Loading trial locations.

About this study

Case management for the treatment of childhood acute respiratory infections has been widely promoted in many developing countries for over 20 years. Despite this, pneumonia continues to claim over 1.5 million lives of children under five annually. The use of affordable, easily-administered, safe, effective treatments can potentially reduce the burden of childhood pneumonia. The WHO recommends the use of a single antibiotic for the treatment of severe pneumonia. Whereas in Asia, evidence from large randomized clinical trials has changed policy recommendations for treatment of severe pneumonia from parenteral penicillin to oral amoxicillin, there is little evidence to inform a similar move in African children where pneumonia is associated with poorer outcomes. In this study the investigators will investigate effectiveness of oral amoxicillin versus the current standard treatment, benzyl penicillin in severe childhood pneumonia using a randomized controlled non-inferiority design preceded by a pilot pre-intervention phase. The investigators will also collect observational data HIV-exposed / infected children with severe pneumonia. 594 children aged 2 - 59 months admitted with clinical signs of severe pneumonia to up to 7 hospitals in Kenya will be randomly assigned to receive either oral amoxicillin or injectable benzyl penicillin. They will then be followed up for the primary outcome of pre-defined treatment failure at 48 hours. The results of this trial will provide valuable data on the effectiveness of oral amoxicillin in the treatment of severe pneumonia in a population of Kenyan children and determine the practicability of conducting large pragmatic trials on pneumonia in Africa similar to those done in Asia.

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Clinical signs of WHO-defined severe pneumonia
  • Age 2 months to 59 months

Exclusion criteria

  • Clinical signs of WHO-defined very severe pneumonia
  • Clinical or laboratory diagnosis of meningitis
  • Clinical diagnosis of severe malnutrition (marasmus/kwashiorkor)
  • Clinical or laboratory diagnosis of severe anaemia requiring transfusion
  • HIV-exposure on rapid HIV antibody test (only observational data will be collected from these patients)
  • Elimination of signs of severe pneumonia in a child with wheeze after outpatient bronchodilator therapy
  • Chronic condition that may underlie or contribute to a presentation with respiratory distress such as: known chronic renal or cardiac disease, presence of cerebral palsy predisposing child to aspiration/hypostatic pneumonia
  • Established bronchiectasis or congenital abnormality of the lower respiratory tract
  • Upper airway obstruction producing stridor
  • Admission from outpatient clinic specifically for treatment of TB
  • Referral from another inpatient facility following treatment with injectable antibiotics for more than 24 hours or because the initial regimen is considered to have failed
  • Documented history of >48hours treatment with oral amoxicillin
  • Failure to obtain informed consent
  • Penicillin allergy

Treatment and study plan

Amoxicillin

Drug

Oral 45mg/kg 12 hourly

Benzyl penicillin

Drug

Intravenous 50,000IU/kg 6 hourly

Primary outcomes

  1. Treatment Failure at 48 Hours (Two Full Days After Enrollment)

    Time frame: 48 hours

    Development of any signs of very severe pneumonia at any time Hypoxemia defined as SpO2 <85% or <80% for altitude < or ≥1500m respectively measured after minimum of 3 minutes on ambient air Persistent vomiting (occurring within 30 minutes of administration of amoxicillin with failure to retain drug after 3 successive attempts at administration) at any time Clinical diagnosis of new bacterial co-morbid condition requiring revision of antibiotic treatment at any time Lower chest wall indrawing Temperature ≥38◦C Respiratory rate ≥5bpm of admission rate if above age-adjusted normal upper limit

Secondary outcomes

  1. Treatment Failure at or Before Discharge / Day 5 Post Enrollment (Whichever Occurs First)

    Time frame: Patients will be followed up from the day of hospitalisation (day 0) until the day of medical discharge (average duration of 3 days) or until day 5 of hospitalisation (whichever occurs first).

    Treatment failure as defined in the primary outcome measure.

  2. Readmission With Diagnosis of Severe or Very Severe Pneumonia Within 14 Days of Enrollment

    Time frame: Day 0 to Day 14

  3. Death at or Before Five Days Following Enrollment

    Time frame: Day 0 to Day 5

    Death defined as: in-hospital death occurring at any time after randomisation (recruitment for HIV-exposed participants) or verbal report of death of the enrolled patient from parent/guardian communicated either directly or via telephone conversation.

  4. Outcome (Death/Readmission) at 14 Days as Determined by Telephone or Direct Interview

    Time frame: Day 14

    Definition of death as described in third secondary outcome measure.

Sponsors and collaborators

Lead sponsor

KEMRI-Wellcome Trust Collaborative Research Program

Other

Collaborators

  • London School of Hygiene and Tropical Medicine
  • University of Nairobi
  • University of Oxford

Registry information

Official study title

Amoxicillin Versus Benzyl Penicillin for Severe Childhood Pneumonia Amongst Inpatients: An Open Label Randomised Controlled Non-inferiority Trial

Important dates

Study start
2011
Primary completion
2013
Study completion
2013
First posted
Jul 22, 2011
Registry last updated
Feb 13, 2015

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.